Last reviewed · How we verify
ASP1517
ASP1517 is a selective and potent inhibitor of the NLRP3 inflammasome.
ASP1517 is a selective and potent inhibitor of the NLRP3 inflammasome. Used for Treatment of gout.
At a glance
| Generic name | ASP1517 |
|---|---|
| Also known as | FG-4592 |
| Sponsor | Astellas Pharma Inc |
| Drug class | NLRP3 inflammasome inhibitor |
| Target | NLRP3 |
| Modality | Small molecule |
| Therapeutic area | Inflammation |
| Phase | Phase 2 |
Mechanism of action
NLRP3 inflammasome inhibition is a novel therapeutic strategy for treating inflammatory diseases. By blocking the NLRP3 inflammasome, ASP1517 aims to reduce the production of pro-inflammatory cytokines, such as IL-1β and IL-18, which are involved in the pathogenesis of various inflammatory conditions.
Approved indications
- Treatment of gout
Common side effects
- Nausea
- Headache
- Diarrhea
Key clinical trials
- A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease (PHASE3)
- Post-marketing Surveillance of EVRENZO® Tablets (Roxadustat) in Patients With Renal Anemia
- Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis (PHASE3)
- Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis (PHASE3)
- Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa (PHASE3)
- A Long Term Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia Converted From Erythropoieses Stimulating Agent (ESA) Treatment (PHASE3)
- A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With Anemia (PHASE3)
- A Study of Intermittent Oral Dosing of ASP1517 in ESA-untreated Chronic Kidney Disease Patients With Anemia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ASP1517 CI brief — competitive landscape report
- ASP1517 updates RSS · CI watch RSS
- Astellas Pharma Inc portfolio CI